Alzheimer’s affects over seven million Americans—a number expected to double by 2050. New FDA-approved drugs and early-detection blood tests give families hope, but government red tape still stands in the way. The Market Institute believes patients and doctors—not bureaucrats—should decide when to use lifesaving innovations. Empowering access to modern treatments isn’t just good policy—it’s the compassionate choice.
Market Institute President Charles Sauer is calling on Congress to make Alzheimer’s early detection a priority when lawmakers return from August recess. In a new op-ed for the Daily Caller, Sauer argues that Congress should Read more…
President Trump’s “liberation” tariffs are already raising costs for American businesses and consumers. Small manufacturers like Bunch Bikes in Denton, Ohio have seen production costs jump more than $1,000 per bike. Polls show 72% of Read more…
Market Institute Senior Fellow Norm Singleton is sounding the alarm over “Kids Over Clicks,” the first major policy proposal from Project 2029, a Democratic effort to develop a governing agenda for the next Democratic president. Read more…
Market Institute President Charles Sauer joined Steve Gruber to discuss the spending battle on Capitol Hill and how healthcare reform could help bring skeptical Republicans on board. Sauer argues that while lawmakers fight over a Read more…
As Congress debates the future of Reconciliation 3.0, Republicans face mounting pressure to balance fiscal discipline with advancing their legislative agenda. In a new Washington Examiner op-ed, Market Institute President Charles Sauer argues lawmakers don’t Read more…
The push to protect children online has become the latest justification for expanding government authority over the internet. In a new RealClearMarkets column, Market Institute Senior Fellow Norm Singleton argues that proposals requiring identity verification Read more…
6151 Fuller Court #8
Alexandria, VA 22310
The Market Institute
info@marketinstitute.org